Salivary Lipid Biomarkers Shifted Toward Typical Levels in Children With Autism After Medical Cannabis Treatment
In an observational study of 15 children with ASD treated with medical cannabis, 22 lipid-based biomarkers in saliva shifted toward levels seen in typically developing children, with network analysis suggesting involvement of inflammation and oxidative stress pathways.
Quick Facts
What This Study Found
22 potential lipid-based cannabis-responsive biomarkers shifted toward typically developing (TD) physiological levels after medical cannabis treatment. Members from all five lipid subclasses present in saliva were characterized. Network analysis suggested involvement of inflammation/redox regulation and oxidative stress subnetworks. Sphingomyelin changes may indicate a role of cannabis in neuron function.
Key Numbers
N=15 ASD children, N=9 TD controls. 22 lipid-based biomarkers identified. All 5 saliva lipid subclasses represented. THC doses: 0.05-50mg. CBD doses: 7.5-200mg. Treatment duration: 1+ year.
How They Did This
Observational lipidomics study of saliva samples from 15 children with ASD receiving individualized medical cannabis treatment (THC 0.05-50mg, CBD 7.5-200mg) for at least 1 year, compared with 9 age-matched typically developing children.
Why This Research Matters
ASD treatment response is typically measured by subjective behavioral observation. If salivary lipid biomarkers can objectively track treatment response, it could transform how medical cannabis treatment for ASD is evaluated and optimized.
The Bigger Picture
The idea of using saliva metabolomics to objectively measure treatment response is innovative and could apply beyond cannabis to other ASD interventions. The inflammation and oxidative stress pathways identified align with known ASD biology.
What This Study Doesn't Tell Us
Very small sample (15 ASD, 9 TD). Observational design without placebo control. Individualized treatment regimens prevent standardized comparison. Biomarker shifts do not prove clinical improvement. Need larger trials with clinical outcome correlation.
Questions This Raises
- ?Would these biomarkers change similarly in a placebo-controlled trial?
- ?Can salivary lipid biomarkers predict which ASD patients will respond to cannabis treatment?
Trust & Context
- Key Stat:
- 22 salivary lipid biomarkers shifted toward typical levels after cannabis treatment in ASD
- Evidence Grade:
- Small observational study without placebo control. Novel biomarker approach requiring larger validation studies.
- Study Age:
- Published in 2023.
- Original Title:
- The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder.
- Published In:
- Cannabis and cannabinoid research, 8(4), 642-656 (2023)
- Authors:
- Siani-Rose, Michael(3), McKee, Robert(2), Cox, Stephany(2), Goldstein, Bonni, Abrams, Donald, Taylor, Myiesha, Kurek, Itzhak
- Database ID:
- RTHC-04937
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Can saliva tests show if cannabis treatment is working for autism?
This preliminary study found 22 lipid biomarkers in saliva that shifted toward typical levels after cannabis treatment in ASD children, but larger controlled studies are needed to validate this approach.
How does cannabis affect autism biology?
The biomarker patterns suggested cannabis may affect inflammation and oxidative stress pathways, and sphingomyelin changes pointed to possible effects on neuron function.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04937APA
Siani-Rose, Michael; McKee, Robert; Cox, Stephany; Goldstein, Bonni; Abrams, Donald; Taylor, Myiesha; Kurek, Itzhak. (2023). The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder.. Cannabis and cannabinoid research, 8(4), 642-656. https://doi.org/10.1089/can.2021.0224
MLA
Siani-Rose, Michael, et al. "The Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder.." Cannabis and cannabinoid research, 2023. https://doi.org/10.1089/can.2021.0224
RethinkTHC
RethinkTHC Research Database. "The Potential of Salivary Lipid-Based Cannabis-Responsive Bi..." RTHC-04937. Retrieved from https://rethinkthc.com/research/siani-rose-2023-the-potential-of-salivary
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.